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E-mail: drkk@snmail.orgInhibition of the interaction between p53 and HDM2 is an
effective therapeutic strategy in cancers that harbor a wild-
type p53 protein such as retinoblastoma (RB). Nanoparticle-
based delivery of therapeutic molecules has been shown to be
advantageous in localized delivery, including to the eye, by
overcoming ocular barriers. In this study, we utilized biocom-
patible gold nanoparticles (GNPs) to deliver anti-HDM2
peptide to RB cells. Characterization studies suggested that
GNP-HDM2 was stable in biologically relevant solvents and
had optimal cellular internalization capability, the primary
requirement of any therapeutic molecule. GNP-HDM2 treat-
ment in RB cells in vitro suggested that they function by
arresting RB cells at the G2M phase of the cell cycle and initi-
ating apoptosis. Analysis of molecular changes in GNP-
HDM2-treated cells by qRT-PCR and western blotting revealed
that the p53 protein was upregulated; however, transactivation
of its downstream targets was minimal, except for the PUMA-
BCl2 and Bax axis. Global gene expression and in silico bio-
informatic analysis of GNP-HDM2-treated cells suggested
that upregulation of p53 might presumptively mediate
apoptosis through the induction of p53-inducible miRNAs.
INTRODUCTION
Retinoblastoma (RB), which is caused by mutations in the RB1 tumor
suppressor gene, is the most common pediatric eye cancer. The two
main aims of treating RB are to prevent the spread of the disease, or
metastasis, and to preserve vision. Enucleation is the main treatment
modality in advanced stages of the disease, when the tumor occupies
important regions of the visualﬁeld and is limited toone eye.1,2 Chemo-
therapy is preferred when a germlinemutation is identiﬁed that predis-
poses the patient to develop secondary cancers.3–6 However, some
patients present with tumors that do not occupy themajor visual ﬁelds,
and, in these patients, localized targeted therapies are possible. Recently,
several studies have focused on either activating tumor suppressors or
suppressing other oncogenes to aid in the treatment of RB.7–9Molecular Thera
This is an open access article under the CC BY-NC-An oncogene that is highly expressed in most cancers, with some
evidence in RB tumors, is human double minute 2 (HDM2).10–13 Un-
der normal conditions, cellular homeostasis is established by way of a
feedback loop involving HDM2 and p53. However, during tumori-
genesis, the feedback loop is lost, either due to the ampliﬁcation of
HDM2 or due to mutations in p53. Inhibition of the HDM2 protein
or blocking its interaction with p53 would be useful when HDM2 is
overexpressed, but not when a wild-type p53 is absent.14 In almost
all RB tumors, a wild-type p53 protein is present; however, it is
rendered non-functional because of the interaction of HDM2, leading
to its ubiquitination and eventually to its degradation.15,16 Therefore,
targeting HDM2 in RB is a potential therapeutic strategy.17–19
Previous studies employing small molecules and HDM2 peptides
have revealed that blocking p53 and HDM2 interaction leads to
reduced cell proliferation and increased apoptosis in RB cells.10,20,21
Earlier, a transducible peptide incorporating the TAT sequence was
used for the delivery of anti-HDM2 peptide.10 Although the study
revealed a signiﬁcant functional effect, the presence of the positively
charged amino acids arginine and lysine in the TAT peptide
(YGRKKRRQRRR) make them vulnerable to cleavage by proteolytic
enzymes, which might necessitate repeated administration of the pep-
tides.22 Therefore, stability of the peptide needs to be considered for
sustainable and effective therapeutic response. In particular, with
respect to ocular delivery, several physiological and anatomical bar-
riers exist that restrict the dispersion and bioavailability of drugs
including peptides. Therefore, use of non-invasive approaches suchpy: Nucleic Acids Vol. 9 December 2017 ª 2017 The Author(s). 349
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic Acidsas microneedles, transscleral diffusion, and iontophoresis, coupled
with nanoparticle-based drug conjugates, might be advantageous
for overcoming ocular barriers and also for increasing the efﬁciency
and availability of the drugs delivered intraocularly.23–26
Gold nanoparticles (GNPs) have been advocated for therapeutic
agent delivery owing to their large surface-area-to-volume ratio,
which enables adsorption of several hundred molecules on its surface.
However, studies have shown that synthetic chemicals used in the
synthesis of GNPs are not suitable for many biological applications
owing to their toxicity. We have earlier reported a rapid method for
the synthesis of GNPs using the extracts of Vitis vinefera L. GNPs
thus synthesized were found to be non-toxic and biocompatible to
normal retinal glial cells.27 In this study, we utilize biocompatible
GNP-synthesized Vitis vinefera L. to deliver HDM2 peptide and
establish the therapeutic potential of GNP-HDM2 in RB through
functional knockdown of HDM2 protein. In addition, we provide
insight on the molecular mechanisms that may be engaged during
the functional HDM2 knockdown by GNP-HDM2 treatment of
RB, by global gene expression analysis.
Our results indicate that GNP-HDM2 is functional and affects the
survival of RB by inhibiting cell proliferation by arresting cells at
the G2M phase and accentuating the apoptotic program through
the PUMA-BCL2-BAX axis. Additionally, global gene expression
analysis indicated that mitotic cell phase, ubiquitin-mediated proteo-
loysis, endocytosis and p53-mediated tumor suppressor microRNAs
(miRNAs), are involved in the functional effects observed. The cur-
rent study establishes the functional effect of GNP-HDM2 on RB,
using a Y79 cell line model and investigating the possible molecular
mechanistic network orchestrating the therapeutic response.
RESULTS
HDM2 Expression Analysis in RB Tumors
The data on HDM2 overexpression in RB tumors from different
studies are inconsistent.13,28,29 Hence, we attempted to study
HDM2 expression in a clinically well-deﬁned cohort (Tables S1A
and S1B) by gene and protein expression, to rationalize its potential
for targeted therapy in RB. The gene expression analysis of RB tumors
revealed that HDM2 was signiﬁcantly overexpressed in RB cells
compared to normal cells (Figures 1A and 1B). Nine out of 10 RB tu-
mors analyzed showed a greater than 2-fold increase in the HDM2
gene expression compared to normal retina. Since functioning of
HDM2 requires the HDM2 protein to be translated, we analyzed
the expression of HDM2 protein in the RB tumors. In line with the
gene expression, the protein expression analysis revealed overexpres-
sion of HDM2 in all the ﬁve samples analyzed compared to normal
retina (Figures 1C–1E).
In Vitro Characterization and Functional Study of GNP-HDM2
GNPs were conjugated to different molar concentrations of the
HDM2 peptide at a ratio of 1:1, 1:2, and 1:3 (GNP:HDM2), and the
shift in the absorption maxima (lmax) was analyzed using UV-visible
(UV-vis) spectrophotometery (Figure S1). There was no signiﬁcant350 Molecular Therapy: Nucleic Acids Vol. 9 December 2017difference in the lmax between GNP 1:1 and 1:2, whereas 1:3 showed
a visible difference in lmax peak intensity that did not change signif-
icantly with increasing peptide concentration. Hence, 1:3 was consid-
ered the ratio of saturation and chosen for further experimentation.
Surface plasmon resonance (SPR-lSPR) of GNP-HDM2 at
535–540 nm showed a signiﬁcant increase in the absorbance at 1:3
(Figure S1A). The presence of free HDM2 peptide could directly
interfere with the functioning of GNP-HDM2, therefore the conju-
gate was subjected to ultracentrifugation (30,000 rpm for
2030 min). Spectroscopic analysis at the absorption maxima of
220 nm (lmax for free peptide) of the supernatants revealed no
speciﬁc peak, indicating absence of free peptide in the conjugates pre-
pared (data not shown). A red shift from 532 nm indicates loading
of the peptide onto the GNP (Figure 2A), owing to the increase in
absorbance at the lmax (Figure S1A). In addition to UV-vis spectro-
scopic analysis, the GNP and GNP-HDM2 were characterized by
dynamic light scattering (DLS), Fourier-transform infrared spectros-
copy (FTIR), X-ray photoelectron spectroscopy (XPS), and transmis-
sion electron microscopy (TEM) analysis.
DLS Analysis of GNP-HDM2
The hydrodynamic diameters (HD) and polydispersity index (PDI) of
GNP-HDM2, GNP:Scb, and GNP were measured using DLS. The
observed HD was 66.72 ± 2.83 with a PDI of 0.303 and 50.40 ±
2.190 with a PDI 0.37 for GNP:HDM2 and GNP:Scb, respectively.
The GNP revealed a HD of 24.47 ± 0.028 with a PDI of 0.388. The
size distribution of GNP-HDM2 (Figure 2B), GNP (Figure 2C), and
GNP-Scb (Figure S1B) were 32–122, 8–19, and 18–80 nm, respec-
tively. An increase in HD of GNP-HDM2 and GNP-Scb compared
to GNP indicates the presence of peptide on the surface of GNP.
The presence of non-polar amino acid such as L in HDM2 peptide
and V, P, and L in the Scb peptide allows for a p-p interaction
between the peptide and the GNP, which might explain the larger
HD in GNP-HDM2 and GNP-Scb.30
Similarly, the zeta potential (z) was obtained 11.4, 18.2, and
16.7 mV for GNP-HDM2, GNP, and GNP-Scb (Figures
S1C–S1E). Overall, the change in the HD, size distribution and zeta
potential was in accordance with the SPR shift observed in case of
GNP-HDM2 and GNP-Scb compared to GNP. The auto correlation
g1 (t), curve (Figures S2A–S2C) conﬁrms monomodal distribution,
and conﬁrmed GNP, GNP:Scb, and GNP:HDM2 were monodispered
and spherical.
FTIR Analysis of GNP-HDM2
FTIR was performed to identify the functional groups present in the
GNP-HDM2 and GNP-Scb conjugate. The major functional groups
present in the conjugate and in HDM2 and Scb peptides are listed
in Table S2A (Figures S3A and S3B). The FTIR spectra of GNP-
HDM2 and GNP-Scb showed broad spectral features at 3,918,
3,410, and 3,402 cm1, which are attributed to the N-H stretching
vibration in GNP-HDM2 and GNP-Scb. The band at 2,146 cm1
shifted to 2,134 cm1 for GNP-HDM2, because of the Au-S bond
Figure 1. Expression of HDM2 in Retinoblastoma
Tumors
(A) qRT-PCR revealed a greater than 2-fold (log2 = 1)
increase in 9 out of 10 RB tumor samples. log2 values
were calculated using the delta-delta Ct method with
b-actin as the endogenous control and normal cadaveric
retina as the calibrator. (B) The expression of HDM2
transcripts was significantly upregulated in retinoblas-
toma compared to the control (normal cadaveric retina)
(p = 0.0031; two-tailed t test). (C) Western blotting of
HDM2 and b-actin revealed increased HDM2 protein
expression in RB (n = 5) compared to the control (normal
cadaveric retina; n = 2). Lanes: T1–T5: RB tumors, C1,
C2: control (normal cadaveric retina). (D) The relative in-
tensity of HDM2 protein normalized to endogenous
b-actin levels was higher in RB compared to the control.
(E) Expression of HDM2 protein in RB was significantly
upregulated compared to the control (p = 0.0289; two-
tailed t test).
www.moleculartherapy.orgfrom the mercaptopropionic acid linker to the peptide. A similar shift
was observed in GNP-Scb from 2,137 cm1 to 2,145 cm1. In addi-
tion to these peaks, additional peaks were observed in the range
1,041–1,053 cm1 and 798–644 cm1, which indicates the presence
of sulfur functional groups in the peptide.31,32
There was a shift toward higher frequency with respect to the
carbonyl amide vibration in GNP-HDM2 (1,654 cm1) and
GNP-Scb (1,656 cm1) compared to HDM2 (1,650 cm1) andMolecular Therascb peptide (1,649 cm1), respectively, which
was attributed to the involvement of
peptide bonding with GNP. In addition,
508–496 cm1 exclusively observed in the
ﬁngerprint region of GNP-HDM2 also sup-
ported bond formation between the GNPs
and the HDM2 peptide.
XPS Analysis of GNP-HDM2
XPS analysis was carried out on GNP and
GNP-HDM2 to establish the nature of the
chemical bonds in the particles. A wide XPS
scan showed the spectra of the major peak
C1s, O1s, and N1s and higher resolution
spectra for the Au4f and S2p in GNP and
GNP-HDM2 (Figures 3A–3F). In the high-res-
olution spectra of the Au4f region of GNP, two
different peaks were observed at 83.44 and
87.00 eV (Figures 3A–3C), and similar peaks
were observed for GNP-HDM2 at 84.30 and
87.30 eV, corresponding to Au4f7/2 and
Au4 f 5/2 for Au0 and Au 1+, respectively (Fig-
ures 3D–3F). Neutral atoms or small-sized par-
ticles of gold show the Au0 state. It is assumed
that disulphide of the MPA linker of HDM2peptide leads to oxidation of the GNPs, which changes Au (0) to
Au (1) in the GNP-HDM2-conjugated state for Au4f7/2.33,34 The
peak of 84.30 eV for Au4f7/2 suggests the presence of an Au-S
bond in GNP-HDM2.35,36 However, the higher binding energy at
87.00 and 87.30 eV corresponds to a Au3+ oxidative state of the
Au. For the S2p region, the peak at 164.75 in GNP represents sulfur
(S-S) species, which indicates that proteins are present in the
reducing agent (Vitis vinifera L.) of GNP. The presence of high bind-
ing energy S2p peaks at 167–168 eV indicates the presence ofpy: Nucleic Acids Vol. 9 December 2017 351
Figure 2. UV-Visible Spectroscopy and Dynamic
Light Scattering Characterization of GNP-HDM2
(A) UV-visible spectroscopy of GNP-HDM2 and the GNP
was carried out. A shift of 5 nm was observed in the
surface plasmon resonance (SPR) peak in GNP-HDM2
(red line) with respect to the GNP (black line). (B and C)
Dynamic light scattering (DLS) data show the size of
nanoparticles (% number distribution) in GNP-HDM2 (B)
and the GNPs (C). See also Figures S1, S2, and S5.
Molecular Therapy: Nucleic Acidssulfones (S-O), afﬁrming the oxidation of the S2p peak. This con-
ﬁrms the self-assembly of HDM2 peptide on GNP.37–39 Taken
together, the XPS analysis conﬁrmed the conjugation of the
HDM2 peptide with the GNPs in the GNP-HDM2 conjugate as
revealed by oxidation of Au4f 7/2 and S2p.40
TEM Analysis of GNP-HDM2
TEM was used to determine the shape and the size of both the GNP
and the GNP-HDM2 peptide. Both GNP and GNP-HDM2 were
spherical in shape and were approximately 12–15 nm in size (Figures
3G and 3H). TEM also revealed internalization of the particles inside
the cells and the absence of particle aggregation, a prerequisite for a
stable system.
MALDI-TOF Analysis of GNP-HDM2 and In Silico Molecular
Dynamics Studies
MALDI-TOF analysis of the GNP and GNP-HDM2 conﬁrmed the
binding of HDM2 peptide with the GNPs. The molecular weight
of HDM2 peptide is 1,565.70. In the MALDI-TOF analysis, the
most intense peak was observed at 1,553.39 m/z with several multi-
plet near the peak (Figures S4A and S4B). We hypothesized that
there is a possibility of some rearrangement which could lead to
the change in the mass of peptide after binding to the GNPs. To un-
derstand this difference, we predicted the structure of the peptides
by simulation using GROMACS (v.4.5) suite.41,42 The in silico data
conﬁrmed that the peptide is linear in structure (Figures S4C and
S4D). However, the presence of aromatic rings of the amino acids352 Molecular Therapy: Nucleic Acids Vol. 9 December 2017(Phe [F] and Trp [W]) in the HDM2 peptide
showed greater ﬂuctuations,43 which in turn
was reﬂected as a shift in the m/z value
(1,553.39 instead of 1,565.70) of the most
intense peak of the peptide on the GNP. The
other common peaks (m/z) between the GNP
and GNP-HDM2 correspond to major com-
pounds present in reducing agent (Vitis
vinifera extract) used in GNP preparation
(Table S2B).44
Hyperspectral Imaging of GNP-HDM2
Hyperspectral imaging of GNP-HDM2was car-
ried out to understand the distribution of GNP-
HDM2 and GNP in cells 24 hr post-treatment
(Figures S4E and S4F). The results suggestthat the particles are uniformly distributed in both the groups sug-
gesting the stability of the GNP-HDM2 conjugate.45
Buffer and Ionic Strength of GNP-HDM2
The ionic stability of GNP-HDM2 was studied in different solvents to
conﬁrm its long-term use as a therapeutic biomolecule.46 The ionic
strength of GNP-HDM2 was conﬁrmed by studying the SPR size and
potential using different solvents that are relevant to cellular applica-
tion. The SPR (lSPR) position for different solvents is shown in Fig-
ure 3I. The lmax was535–537 nmwith no considerable shift (either
red or blue) in SPR peak position in all solvents tested, conﬁrming the
stability and lack of change in the optical properties of GNP-HDM2. In
the presence of the polar amino acids histidine and cysteine, the zeta
potential was 25.6 ± 1.59 mV and 19.7 ± 2.30 mV, respectively,
indicating bond formation between polar amino acids and GNP-
HDM2. Similarly, DTT also increased the negative zeta potential
from 11.4 to 48.1 ± 0.5 mV. The increased negative potential in
the presence of DTT (48.1 ± 0.5 mV) and amino acid conﬁrmed
the stability of GNP-HDM2 in polar solvents and strong reducing
agents, respectively. Similarly, a change in zeta potential was reported
in nitrogen doped carbon with DTT functionalized.47 As reported,
anionic DTT increased the negative potential, whereas in the presence
of NaCl, a high ionic strength salt, the zeta potential did not alter as
much as in the other solvents and amino acids. NaCl maintained the
electric double layer onGNP-HDM2anddidnot alter the ionic stability
of GNP-HDM2.48,49 In contrast, fetal bovine serum (FBS) signiﬁcantly
decreased the negative zeta potential7.80 ± 0.77 mV, which could be
(legend on next page)
www.moleculartherapy.org
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Table 1. Ionic and Solvent Stability of GNP-HDM2
S. No. Solvent Z Averagea Zeta Potential (mV)
1 GNP-HDM2 +NaCl 54.79 ± 0.81 13.6 ± 0.87b
2 GNP-HDM2 +cysteine 53.51 ± 0.26 19.7 ± 2.30b
3 GNP-HDM2 +histidine 41.64 ± 0.28 25.6 ± 1.59b
4 GNP-HDM2 +DTT 44.57 ± 0.18 48.1 ± 0.5b
5 GNP-HDM2 +10% FBS 57.14 ± 3.23 8.26 ± 0.2c
6 GNP HDM2 +50% FBS 23.40 ± 0.56 7.80 ± 0.77c
7 GNP-HDM2 66.72 ± 2.83 11.43 ± 0.55
The change in zeta potential toward more negative (13.6 ± 0.87 mV to 48.1 ± 0.5 mV)
compared with GNP-HDM2 (11.43 ± 0.55 mV) conﬁrmed the stability of GNP-
HDM2 in highly ionic solvents and buffers.
aZ average indicates the intensity-based mean hydrodynamic size of GNP-HDM2 sub-
jected to the solvent type.
bIndicates electric bilayer of different solvents on GNP-HDM2. The zeta potential
increased toward more negative.
cIndicates the FBS coating on GNP-HDM2 that changed the zeta potential toward less
negative. This ﬁnding conﬁrms the binding of the FBS protein to GNP-HDM2.
Molecular Therapy: Nucleic Acidsdue to binding or coating of FBS proteins on GNP-HDM2 (Table 1).
Overall, the change in zeta potential and its magnitude indicated the
colloidal stability of GNP-HDM2 in various biologically relevant solu-
tions, making these acceptable for their biological applications.50
Functional Effect of GNP-HDM2 and GNP on Y79 Cell Lines
Our earlier study on non-cancerous retinal glial (MIOM1) cells iden-
tiﬁed a concentration of 50 mM GNP to be non-toxic at the end of a
24-hr treatment. Hence that concentration was used to prepare GNP-
HDM2. Y79 cells were treated with 50 mMGNP and GNP-HDM2 for
24 hr and the cells were analyzed for apoptosis and cell proliferation
by Annexin V-PI and PI-Ribonuclease staining, respectively. The
fraction of cells in G0/G1; S; G2M phases were analyzed to reveal
the effect of GNP and GNP-HDM2 on the cell-cycle analysis. The re-
sults did not reveal any major difference between the different cell
phases between the groups, however, a statistically signiﬁcant
decrease in the cells in G1 phase (p = 0.0217; one-way ANOVA)
with concomitant increase in the G2M phase (p = 0.0142; one-way
ANOVA) in GNP-HDM2-treated cells compared to control, suggest-
ing that GNP-HDM2 might function by arresting cells at the G2/M
phase (Figures 4A–4D). However, the difference was not signiﬁcant
between the GNP- and GNP-HDM2-treated cells.
The analysis of the Y79 cells treated with GNP and GNP-HDM2 for
apoptosis revealed that there was a signiﬁcant increase in the cellsFigure 3. X-Ray Photoelectron Spectroscopy and Transmission Electron Micro
(A–F) A wide XPS scan showed the spectra of the major peak C1s, O1s, and N1s (A) and
the GNPs. In the high-resolution spectra of the Au4f region of the GNPs, two different pe
the major peaks C1s, O1s, and N1s (D); higher resolution spectra for Au4f and S2p (E);
HDM2 at 84.30 and 87.30 eV, corresponding to Au4f7/2 and Au4f5/2 for Au0 and Au 1+
GNP-HDM2 (G) and the GNPs (H) are 12–15 nm in size, with a spherical shape. (I) T
between 535–537 nmwithout any considerable shifts (either red or blue) in all the solvent
See also Figures S3 and S4.
354 Molecular Therapy: Nucleic Acids Vol. 9 December 2017undergoing apoptosis in the GNP-HDM2-treated group compared
to both the control and GNP treated cells (p = 0.0010; one-way
ANOVA and Tukey’s test for multiple group comparisons) (Figures
4E–4H).Analysis of p53 and Its Downstream Targets in the GNP-HDM2
and GNP Treatments
Since, the HDM2 peptide primarily functions by increasing the stabil-
ity of p53 protein.10 We evaluated the transcript levels of p53 in GNP,
GNP-Scrambled peptide (GNP-Scr), and GNP-HDM2 groups,
compared to the untreated control. There was a signiﬁcant increase
in the transcript levels of p53 in GNP-HDM2 and GNP compared
to the GNP-Scr group and untreated control (p = 0.0015, one-way
ANOVA) (Figure 5A). The P53 level was downregulated in GNP-
Scr compared to the untreated control. Hence, GNP was preferred
over GNP-Scr for further comparative analysis.
We further evaluated the levels of p53 protein in the control, GNP and
GNP-HDM2 groups and found that similar to transcript levels, p53
protein was signiﬁcantly increased in both GNP and GNP-HDM2
groups compared to control (p < 0.0001; one-way ANOVA) (Figures
5B and 5C). However, the levels remained comparable between GNP
and GNP-HDM2, which made in depth evaluation of GNP and GNP-
HDM2 groups more important.
Since, p53 transcriptionally activate HDM2,51 we studied its expres-
sion at the gene and protein levels. HDM2 transcripts and protein
were found to be signiﬁcantly downregulated in the GNP-HDM2
group compared to both control and GNP at p < 0.0001,
p = 0.0004, respectively (Figures 5D and 5E). Since, this result was un-
foreseen and encouraging, we screened for other direct p53 transcrip-
tional targets52–54 and related molecules, to know if the p53 arm
was activated. qPCR analysis of p21cip1, PUMA, BAX, BCL2 and
CASP3(Caspase 3) revealed that the increase in the p53 protein levels
did not upregulate p21cip1 in either treatment. With respect to the
p53-dependent apoptotic pathway molecules, PUMA was upregu-
lated in the GNP-HDM2 group compared to both control and
GNP-treated cells (Figure 5F). The levels of BCL2, an indirect target
of p53, and BAX, a direct target of p53,54–56 were both downregulated
compared to the control (Figure 5F). The ratio of BAX:BCL2 was
signiﬁcantly increased in the GNP-HDM2 group compared to both
control and GNP-treated groups, indicating p53-PUMA-BCL2 and
BAX axis molecules were involved in the apoptosis of GNP-
HDM2-treated RB cells (Figure 5F). The decrease in p21cip1 did notscopy of GNP-HDM2
higher-resolution spectra for Au4f and S2p (B) and the original and fitted spectra in
aks were observed at 83.44 and 87.00 eV. A wide XPS scan showed the spectra of
and the original fitted spectra (F) in the GNP-HDM2. Peaks were observed for GNP-
, respectively. (G and H) Transmission electron microscopy (TEM) revealed that both
he stability of GNP-HDM2 in different solvents showed that SPR (lmax) remained
s, confirming a stable optical property in these solvents. Scale bar, 100 nm (G and H).
(legend on next page)
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Molecular Therapy: Nucleic Acidscome as a surprise, since its involvement pertains more to the G1-S
phase transition and the cell-cycle analysis data of the treatments
showed cell-cycle arrest at the G2M phase, without signiﬁcantly
affecting the G1-S phase transition. Overall, the activation of p53
by GNP-HDM2 led to increased apoptosis via activation of PUMA
and the BCL2-BAX axis.
Analysis of Global Gene Expression Effects in GNP-HDM2- and
GNP-Treated RB Cells
To gain further insight into the mechanistic network involved in
GNP-HDM2-treated cells, microarray was performed on the control,
GNP- and GNP-HDM2-treated Y79 cells (GEO: GSE92987). Differ-
ential gene expression analysis between the control and the GNP-
treated group revealed that the molecular proﬁle between the two
groups did not vary greatly, with only 68 genes being differentially ex-
pressed. Of these 68 genes, 65 were upregulated and 3 were downre-
gulated (Figure 6A). Gene ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway analysis did not reveal any
statically signiﬁcant enrichment between the control and GNP-
treated groups, suggesting that the speciﬁc dose of GNP did not
signiﬁcantly alter the molecular proﬁling of the cells. To compare
the differential gene expression between GNP- and GNP-HDM2-
treated cells, gene expression was compared between two groups,
namely GNP versus control and GNP-HDM2 versus control. The
fold change for the genes between GNP versus control (Figures 6A
and 6C) and GNP-HDM2 versus control (Figures 6B and 6D) were
utilized to calculate the fold difference between the GNP and GNP-
HDM2 groups. The analysis revealed that 815 genes were upregulated
and 812 were downregulated in GNP-HDM2 cells, relative to GNP-
treated cells (Figure 6E).
To determine the signiﬁcant biological functions and pathways
involved during GNP-HDM2 treatment, functional analysis by GO,
KEGG pathway, and ingenuity pathway analysis was performed.
GO revealed 194 and 213 terms signiﬁcantly enriched in downregu-
lated and upregulated gene lists, respectively. The ﬁve most overrep-
resented GO terms for biological functions in the downregulated and
upregulated genes are provided in Table S3.
The biological function predominantly enriched in the downregu-
lated genes pertained to the mitotic phase of the cell cycle correlating
with the G2M arrest of the cell-cycle analysis. However, the biological
function analysis on the upregulated genes were broad and pertainedFigure 4. Functional Effects of GNP and GNP-HDM2 on RB Cell Lines
(A–D) RB cells treated with the GNPs and GNP-HDM2 for 24 hr were subjected to cell-c
cells were subjected to cell-cycle analysis by Telford’s method. (D) Cell-cycle analysis
(p = 0.0217; one-way ANOVA) with a concomitant increase in the G2M phase (p = 0.0
control, suggesting that the bioconjugate might function by arresting the cells at the G2/M
treated with GNP and GNP-HDM2 for 24 hr were subjected to an apoptosis assay. Cont
to an apoptosis assay by the annexin V FITC-PI method. (H) An apoptosis assay revea
HDM2-treated group compared to both the control and GNP-treated cells (p = 0.001
represent the mean ± SD of triplicate samples. Lower left: live cells (annexin and PI ).
and PI+). Upper left: necrotic cells (annexin and PI+).
356 Molecular Therapy: Nucleic Acids Vol. 9 December 2017to several physiological functions such as cellular differentiation,
immune response, organ development, indicating that the genes
that are upregulated predominantly orchestrate the conversion of
undifferentiated cells such as tumor into a more differentiated cells
that might have functional implications. The cellular component
ontology clearly differentiated the downregulated and upregulated
gene lists, as the former was predominantly intracellular, including
cytoplasmic, cytoskeletal, and nuclear components, and the latter
was enriched exclusively with extracellular and membrane-bound
proteins (Table S4). Independent analysis using the human protein
reference database conﬁrmed the GO results (Figure 6F). The molec-
ular function ontology revealed predominance of enzymatic func-
tions and receptor activity in downregulated and upregulated gene
sets, respectively (Table S5).
The pathways enriched in the downregulated and upregulated gene
list by KEGG pathway analysis are provided in Table S6. Themost en-
riched pathways in the downregulated set of genes included cellular
processes like the cell cycle, ubiquitin-mediated proteolysis, and
endocytosis. Comprehensive analysis of the genes participating in
ubiquitin-mediated proteolysis revealed that GNP-HDM2 treatment
not only leads to a reduction in HDM2 but also to a reduction in other
E3 ubiquitin ligases such as COP1 and PIRH2, which can individually
target p53 leading to its degradation.57,58 This suggests that there is a
concerted action on the prevention of other ubiquitin ligases from de-
grading p53, leading to increased stability of the p53 protein in the
treated cells. In addition to the downregulation of ubiquitin ligases,
the downregulation of the gene CDC23, which is required for mitosis
and G1 phase of the cell cycle, suggests that the concerted inhibition
of both the cell cycle and ubiquitin-mediated proteolysis may be
attributed to the G2M arrest and increased P53 stability and apoptosis
that were observed in the functional experiments.
In addition to the cell cycle and ubiquitin-mediated proteolysis, a sig-
niﬁcant enrichment was seen in endocytosis in the downregulated
gene lists. Most of the downregulated genes suggest that clathrin-
dependent endocytosis is signiﬁcantly compromised without much
involvement of clathrin-independent endocytosis. Previous studies
on breast cancer show that inhibition of clathrin-dependent endocy-
tosis led to restoration of the death receptors on the cell surface,
thereby sensitizing TRAIL-resistant cells to apoptosis. Several studies
have linked ubiquitination with endocytosis with subsequent degra-
dation of plasma membrane receptors and transporters. It isycle analysis. Control (untreated) (A), GNP-treated (B), and GNP-HDM2-treated (C)
revealed a statistically significant decrease in the number of cells in the G1 phase
142; one-way ANOVA) in the number of GNP-HDM2-treated cells compared to the
phase. Error bar represents the mean ± SD of the triplicate samples. (E–H) RB cells
rol (untreated) (E), GNP-treated (F), and GNP-HDM2-treated (G) cells were subjected
led a significant increase in the number of cells undergoing apoptosis in the GNP-
0; one-way ANOVA and Tukey’s test for multiple group comparisons). Error bars
Lower right: early apoptotic (annexin+ and PI). Upper right: late apoptotic (annexin+
(legend on next page)
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above, contributed to inhibition of the endocytosis process at the
global level. Several studies have shown the efﬁcacy of clathrin-medi-
ated endocytosis inhibitors and dynamin endocytosis inhibitors in
inhibiting tumorigenesis.
In the upregulated set of genes, the most enriched processes involve
metabolism and signal transductions, such as arachidonic acid meta-
bolism, calcium signaling, cytokine-cytokine interactions and olfac-
tory transduction. With respect to arachidonic acid metabolism in
tumorigenesis, several studies indicate a pro-tumorigenic role. How-
ever, with respect to RB, one study revealed that arachidonic acid
increases oxidative stress in Y79-RB1 cells and promoted its
apoptosis. It was shown that activation of PLA2 by the drug melittin
led to apoptosis of RB cells. In the arachidonic acid pathway, upregu-
lation of three different PLA2s, namely PLA2 group IIA, PLA2 group
IIC, and PLA2 group IID, suggested that they inﬂuence the apoptotic
mechanism in these cells. With respect to olfactory transduction, re-
ports suggest that olfactory receptors are widely expressed in tissues
other than sensory neurons of the olfactory epithelium, however,
their functional relevance in these tissues have not been established.
In the context of tumorigenesis, there are contradictory reports on
the activation of olfactory receptors and promotion or inhibition of
tumors. The role of calcium signaling and cytokine-cytokine receptor
interactions in the tumorigenesis is not clear and requires further
evaluation.
To gain insight into common regulators of the global gene expression
post-HDM2 functional knockdown, upstream regulator analysis was
carried out in Ingenuity pathway analysis. Upstream regulator anal-
ysis revealed eleven signiﬁcant master regulator genes governing
the gene expression networks (Fisher’s exact test, p < 0.05). The 11
upstream regulators, their activation/ inhibition status and the class
to which they belong are shown in Table S7. Of the 11 regulators,
8 showed activation, and 3 showed inhibition. The role of these up-
stream regulators in cancer is compiled in Table S7. Based on their
roles in cancer, eight out of the eleven upstream regulators had tumor
suppressor or anti-tumorigenic properties, while three had tumori-
genic or tumor invasive properties. In addition to their roles in cancer,
their relation to the p53-HDM2 axis revealed that 8 out of 11 regula-
tors played important roles in modulating the p53-HDM2 axis or
p53-directed downstream processes.
Detailed analysis revealed that p53-dependent activation of tumor
suppressor miRNAs miR16-5p, let-7, mitochondrial protein, and
interactive chromatin modiﬁer SMARCB1 potentiate tumor suppres-Figure 5. Analysis of p53 and Its Downstream Targets in the GNP- and GNP-H
(A) Analysis of P53 by quantitative real-time PCR showed a significant increase in the P
control (p = 0.0015; one-way ANOVA). (B) Representative western blot of p53 and H
(C) Analysis of p53 protein in both GNP- and GNP-HDM2-treated RB cells revealed
transcripts (D) and protein (E) revealed that, while the HDM2 gene and protein expres
significant decrease in HDM2 expression. (F) qRT-PCR analysis of possible downstrea
apoptosis; however, p21 expression was not significantly affected.
358 Molecular Therapy: Nucleic Acids Vol. 9 December 2017sion and apoptosis (Table S7). Concordantly, inhibition of the axis
activating HDM2, namely ESR1 and RABL6, may also contribute to
tumor suppression (Table S7). In contrast, the direct targets of
p53, namely NUPR1 and TCF3, might enhance tumorigenesis and
chemoresistance, inadvertently increasing metastasis of the tumor
(Table S7).
Since, the upstream regulator indicated p53-dependent miRNA acti-
vation plays a role in tumor suppression, we utilized an in silico
approach to identify miRNA that were highly enriched in the dataset.
For this purpose, we obtained a list of validated miRNA known to
regulate the transcripts that are upregulated and downregulated
post HDM2-GNP treatment. The miRNA were ranked based on
the number of targets they regulated in a given list. The top 5 miRNA
in each group are shown in Table S8. Since, the miRNA is known to
inhibit mRNA expression, the miRNA list was consolidated based on
the following criteria: (1) the miRNA that regulate the genes in the
upregulated transcript list were considered as downregulated and
(2) the miRNA that regulate the genes in the downregulated tran-
script list were considered as upregulated. The in silico analysis
suggested that p53 regulated miRNAs, hsa-miR-192-5p, and
hsa-miR-215-5p showed upregulation along with hsa-miR 16-5p,
whereas hsa-miR-335-5p showed downregulation. The results sug-
gest that HDM2-GNP might in part orchesterate miRNA-based
tumor suppression via p53.
DISCUSSION
Herein we report the preparation, characterization and functional ef-
ﬁcacy of GNP-HDM2 in RB. Our results indicate that GNP-HDM2
can reactivate wild-type p53 whose expression is compromised in
RB tumors. Characterization of GNP-HDM2 revealed several advan-
tages in utilizing it for intraocular treatment of RB. Assessment of the
zeta-potential of GNP-HDM2 conﬁrmed its stability in biologically
relevant solutions. In addition, results of the cellular internalization
by TEM and hyperspectral imaging, alongside its functional attributes
on the cell cycle and apoptosis results suggested that the conjugate
increased the stability of the peptide by protecting it against protease
degradation, thereby increasing its delivery into the cytosol.
It has been observed that zeta potential showed a decrease in negative
potential with11.4 mV in GNP-HDM2 and18.2 mV in the GNP,
which might enhance internalization of the peptide.59–61 A similar
retention of overall negative charge has been reported, without
compromising the biological function of the peptides or proteins.
These studies showed that the overall negative potential of the
GNP-peptide conjugates can be attributed to incompleteDM2-Treated RB Cells
53 transcript levels in GNP-HDM2 and the GNPs over GNP-Scb and the untreated
DM2 proteins in the control (untreated), GNP-, and GNP-HDM2-treated RB cells.
an increase in p53 protein after both treatments. (D and E) Analysis of the HDM2
sion increased in GNP-treated cells, the cells treated with GNP-HDM2 showed a
m targets of p53 revealed that the PUMA-BCl2-Bax axis led to caspase-mediated
Figure 6. Global Gene Expression Analysis of GNP-HDM2 Treatment on Retinoblastoma Cells
(A) A volcano plot revealed 68 differentially expressed genes with 65 upregulated and 3 downregulated in GNP-treated cells compared to the control at a fold change ofR 2
and p value < 0.05. (B) A volcano plot revealed 4,461 differentially expressed genes with 1,161 upregulated and 3,300 downregulated in GNP-HDM2-treated cells compared
(legend continued on next page)
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Figure 7. Schematic Representation of Presumptive Molecular Mechanism
Orchestrated by GNP-HDM2 Treatment in Retinoblastoma
Predominant downstream targets of p53, upstream regulators, and miRNA identi-
fied by IPA analysis and in silico miRNA analysis are presented. Arrows indicate
activation; straight line with bars indicate inhibition; dotted lines in arrow/bar indicate
abrogation of the expected effect; green boxes reveal miRNA identified by in silico
analysis; light-brown boxes reveal the molecules identified as upstream regulators
by IPA analysis; light-blue ovals are validated by qPCR and/or western blotting;
white and pink fonts indicate favorable and unfavorable molecules for tumor
suppression, respectively; and yellow boxes indicate a functional outcome.
Molecular Therapy: Nucleic Acidsneutralization of the positive charge of the BBN peptide and TNF
factors which were conjugated to the GNP.36,62
Our results on GNP-HDM2 treatment in an RB1 cell line conﬁrmed
that the nano-bio-conjugate interfered with the ubiquitin-mediated
proteolysis of p53, thereby upregulating the p53 protein. Similar
results of stable upregulation of p53 expression was recognized in pre-
vious studies employing peptides or small molecules against
HDM2.63–65 However, while the previous studies reported an
increased transactivation of a wide range of downstream targets of
the p53 protein, including increased expression of HDM2 transcript
itself, GNP-HDM2 reduced the HDM2 transcript and the protein
levels.
In addition, global gene expression analysis provided evidence of
global suppression of E3 ubiquitin ligases that mediate p53 degrada-
tion. These data suggest that p53 expression was stabilized by sup-
pression of ubiquitin-mediated proteolysis. Although a previous
study utilizing the anti-HDM2 peptide suggested that both p21cip1-to the control at a fold change ofR 2 and p value < 0.05. (C and D) Unsupervised hierarc
control versus GNP-HDM2 (D) groups. (E) Unsupervised hierarchial clustering of differe
ferential gene expression between GNP- and GNP-HDM2-treated cells, gene expressio
were compared. The fold change for the genes between GNPs versus control and GNP
and GNP-HDM2 groups. The analysis revealed that 815 genes were upregulated and 81
The cellular component ontology by the human protein reference database clearly differe
intracellular including cytoplasmic, cytoskeletal, and nuclear components, and the latte
360 Molecular Therapy: Nucleic Acids Vol. 9 December 2017mediated G1-S phase arrest and p53-mediated apoptosis were
involved in the outcome, instead GNP-HDM2 predominantly
orchestrated its functional effect by arresting the cells at the G2-M
phase p53-mediated apoptosis. A study reporting the effect of nutlin
3, a small molecule against HDM2 suggested that cellular response to
nutlin 3 was context speciﬁc. Its treatment on cancer cell lines led to
either cycle arrest or apoptosis, and this event was dependent on the
RB expression and its phosphorylation.46 The absence of RB1 expres-
sion in RB might have led to preferential apoptosis over G1-S cell-cy-
cle arrest. Previous genetic screen for identiﬁcation of pathway-spe-
ciﬁc regulators of p53 activation in different cell lines suggested
that TCF3/E2A expression determine the p21:PUMA ratio upon
p53 activation. The study suggested that depletion of TCF3 led to
an impairment of cell-cycle arrest, while promoting p53 activation.
However, in our study, the upstream regulator analysis suggested
an activation of TCF3 with reversal of the p21:PUMA ratio. We
hypothesize that factors other than TCF3, such as TRIAP1, which
inhibits p21cip1, might be involved in reversal of this role.66 Our
results with the upstream regulator analysis showed a strong correla-
tion of p53-mediated miRNA activation.
The in silico analysis of miRNA using target enrichment analysis
showed good concordance with the upstream regulator analysis.
A study involving nutlin 3a treatment on multiple myeloma showed
that the small molecule based p53 activation in these cells led to acti-
vation of miRNAs such as miR 192 and miR 215, which suppressed
HDM2 expression. This ﬁnding corroborates our observation where
stabilized p53 instead of transactivating HDM2 led to their suppres-
sion, indicating the p53-directed miRNA-mediated suppression of
HDM2. Rigorous functional validation of p53-induced miRNA is
required to conﬁrm this ﬁnding. The overall molecular mechanism
occurring during functional HDM2 knockdown by GNP-HDM2
treatment of RB is summarized as a schematic in Figure 7. In sum-
mary, the results indicate that GNP-HDM2 is effective in suppressing
RB primarily by p53-mediated apoptosis. At this point, the in silico
analysis indicates that miRNAs may be involved in orchestrating
this effect, although we have not validated this experimentally. We
consider the functional validation of these miRNA will serve as an
ideal follow-up study for conﬁrming the mechanism involved.MATERIALS AND METHODS
Ethics Approval
The proposed study was approved by the ethics committee of Vision
Research Foundation-Chennai, India, under the approval number
383-2013-P.hial clustering of differentially expressed genes in the control versus GNP (C) and the
ntially expressed genes between the GNPs and GNP-HDM2. To compare the dif-
n between two groups, namely GNPs versus control and GNP-HDM2 versus control
-HDM2 versus control were utilized to calculate the fold difference between the GNP
2 were downregulated in GNP-HDM2-treated cells relative to GNP-treated cells. (F)
ntiated the downregulated and upregulated genes as the former was predominantly
r was exclusively enriched with extracellular and membrane-bound proteins.
www.moleculartherapy.orgAnalysis of HDM2 Expression in RB Tissues
The HDM2 transcript and protein levels in RB tissues (n = 10) were
analyzed in comparison to normal retina. Brieﬂy, RB tumor samples
were collected from the RB patients who underwent enucleation as
part of their therapy at the Medical Research Foundation, Sankara
Nethralaya (Chennai, India). Informed consent for utilizing the sam-
ples for research purposes was obtained from patients during the
surgical procedure. The clinicopathological details of the patients
included in the study are provided in Tables S1A and S1B. The RB
tumor samples were snap frozen at 80C and stored until use. The
samples were thawed on ice and subjected to RNA and protein extrac-
tion. Cadaveric normal donor retina tissue was obtained from the CU
Shah Eye Bank, Sankara Nethralaya (India). Total RNA was isolated
from 100 mg of tissue using Trizol reagent (Sigma, USA). cDNA was
synthesized from total RNA using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, USA). Quantitative real-time
PCR was performed using the SYBR Green Mix (Applied Biosystem,
USA) usingHDM2 primers. The log2-fold change was calculated using
the DDCT method with GAPDH as an endogenous control, normal-
ized to the control (cadaveric retina). For protein expression, approxi-
mately 250mg of tissue was subjected to homogenization using a radio
immunoprecipitation (RIPA) buffer and subjected to sonication with
10 cycles of 10-s pulses under ice-cold conditions. Protein was esti-
mated using the Bradford’s method. Western blotting was performed
with 50 mg of protein separated on 10%–12% SDS-PAGE using
HDM2 andb-actin antibody. Detailed protocols for qPCR andwestern
blotting are provided in the Supplemental Materials and Methods.
Preparation of GNP-HDM2
HDM2 peptide (QETFSDLWKLLP, 12 amino acids) and a control
peptide (KRLRLDPV, 8 amino acids) named “Scrambled” was
custom synthesized by Sigma-Aldrich (Japan) (OE-14045-001 and
OE-14045-002, respectively) with >95% high-performance liquid
chromatography (HPLC) purged (Table S9). A 3-mercaptopropionic
acid linker was attached to the N-terminal of HDM2 and the Scb pep-
tide, and the observed mass of the peptides was 1,565.7 and 1,085.4
m/z, respectively. Figure S5 shows the schematic representation of
the conjugation of GNPs with the HDM2 peptide. GNP-HDM2
and GNPs-Scb were prepared by mixing functionalized HDM2 and
Scb peptide with GNP, synthesized using Vitis vinefeara L.26 GNP-
HDM2 was prepared by mixing GNPs with peptide: 18 mL of
GNPs (optical density 520 [OD520] = 1.00 nm) (242  106, mol
gold/L) with 4.2 mg of peptide (GNP:HDM2 1:3) (dissolve in 0.01
cell-culture-grade DMSO), with continuous stirring for 24 hr
followed by puriﬁcation using ultra-centrifugation at 30,000 rpm un-
til a clear supernatant was obtained and any unbound peptide was
removed. A similar protocol was followed for the 1:2 and 1:1
GNP:HDM2 by mixing 2.8 and 1.40 mg of peptide, respectively.
The absence of unbound peptide was conﬁrmed by UV-vis spectros-
copy at 220 nm. The pellet was resuspended in the cell culture me-
dium, and OD was measured at 530 nm to get the ﬁnal concentration
of GNP-HDM2 and GNPs-Scb, using GNP as a standard followed by
their characterization. A ﬁnal stock concentration of 50 mg/mL was
prepared for the further experimentation.Characterization of Synthesized GNP-HDM2
UV-vis Spectroscopy
GNP-HDM2 and GNP:Scb were characterized by UV-vis spectros-
copy, and spectral data were collected in the 400- to 800-nm range
at room temperature. A 1-cm light path quartz cuvette was used,
and samples were diluted and OD adjusted (OD520 = 1.00 nm).
DLS
The average hydrodynamic size (Z average), size distribution
(% number distribution), and zeta potential were determined, with
3 measurements being collected for each sample using DLS (Zetasizer
[Nano-ZS model equipped with 4.0 mW, 633 nm laser, Model
ZEN3600, serial no. MAL1024433, Malvern Instruments, Malvern,
UK]).
Fourier Transform Infrared Spectrum
HDM2 and Scb peptides and conjugate GNP:HDM2 and GNP:Scb
were characterized by FTIR (Vortex 70, BRUKER). FTIR was
performed over the range 500–4,000 cm1, in transmittance mode
using potassium bromide (KBr) pellets.
XPS
XPS was performed to determine the chemical bonding states
between the GNPs and the peptide at the surface region. XPS analysis
was performed at the Indian Institute of Science (Banglore, India). An
XPS spectrometer with an Al Ka energy source at 1,486.6 eV, anode
source operated at 250W, and pressure below 2 109 torr was used
for the scans. Samples were prepared by drop-coating of the
GNP:HDM2-conjugated solution on a clean silicon wafer, and the
drops were allowed to air dry. The electron pass energy was set at
0–1,000 eV for wide/survey scans and 180 eV for high-resolution
scans of Au4f and S2p. All XPS spectra were calibrated by calibrating
the charge against the hydrocarbon C1s peak at 284.6 eV as a
reference.
TEM for Cellular Internalization and Characterization
The particle shape and size were further conﬁrmed by TEM. The
GNPs and GNP-HDM2 were prepared by drop-coating on copper
grids and dried overnight. TEM analysis was carried out at an accel-
erating voltage of 200 kV. For the TEM study,1 106 Y79 cells were
cultured in 6-well plates and treated with GNP and GNP-HDM2 for
24 hr. These cells were washed with PBS and ﬁxed in a primary ﬁxa-
tive (2.5% glutaraldehyde prepared using 0.1 M sodium cacodylate
buffer at pH 7.2–7.4.). The detailed TEM analysis protocol is provided
in the Supplemental Materials and Methods.
MALDI-TOF Analysis of GNP-HDM2 and In Silico Molecular
Dynamic Studies
MALDI-TOF Analysis of the GNPs and GNP-HDM2
MALDI-TOF was performed using a cyano-4-hydroxycinnamic acid
(HCCA) matrix for analysis of proteins and peptides. The solvent was
50% MeCN and 0.1% triﬂuoroacetic acid (TFA) in water at 1:1 ratio.
The sample concentration was 10 – 100 pmol/mL. Equal volumes
(1 mL) of HCCA matrix and sample were mixed, and 2 mL of theMolecular Therapy: Nucleic Acids Vol. 9 December 2017 361
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perform the MALDI-TOF analysis using Bruker RapiFleX at Shrim-
pex Multidisciplinary Biotech (Chennai, India).
In silico molecular dynamics of the peptide were performed using
GROMACS. TheAMBER force ﬁeld was employed to calculate the in-
teractions of simulation. The peptide was solvated in a cubic box of
TIP3P H2O, and the charge of the system was neutralized by adding
either chloride or sodium ions. The neutralized systemwasminimized
and then equilibrated with NPT-NVT ensembles. The production run
was initially carried out for 10 ns and extended up to 50 ns depending
on the convergence of the system. The structure for the peptide
sequence was modeled by performing homology modeling with
PDB (PDB: 1YCR) structure as a template. Further, the model was
reﬁned using molecular dynamics simulations. A root-mean-square
deviation (RMSD) plot was used to assess the stability of the model.
Hyperspectral Imaging of GNP-HDM2
Y79 cells cultured in RPMI media on coverslips (Lab-Tek) overnight
were treated with the 50 mM of GNPs and GNP-HDM2 for 24 hours.
Post-incubation, the cells were washed with 1 PBS and ﬁxed in 4%
paraformaldehyde solution. Permanent slides were prepared using
mountant and imaged using the Hyperspectral Imaging System
(Cytoviva) at IITM (India).
In Vitro Ionic and Buffer Stability
GNP-HDM2 was studied in a variety of solvents and buffers to afﬁrm
its stability in vitro for the functional studies, using previously
reported methodology. Brieﬂy, 1 mL of GNP-HDM2 was mixed
with 0.5 mL (10 mM) each of DTT, cysteine, histidine NaCl, and
FBS. GNP alone (without HDM2 peptide) served as the control.
The solutions were then incubated for 2 hr at room temperature,
and the stability of GNP-HDM2 was determined by size and zeta
potential measurement.
Functional Studies Using an In Vitro RB Model
Treatment of Y79 (RB) Cell Lines with GNP-HDM2
The Y79 cell line was obtained from Cell Bank, RIKEN Bio Resource
Centre (Ibaraki, Japan) and cultured in suspension using RPMI 1640
(GIBCO, USA) cell culture media. The culture media was supple-
mented with FBS 10% (v/v) (GIBCO, USA) and 1% antibiotic cocktail
(v/v). All experiments were performed within 5 passages of its
retrieval.
Analysis of p53-HDM2 Axis in GNP-HDM2 in RB-Treated Cells
Real-time PCR and western blotting were performed to check the
expression of HDM2 and P53 in the Y79 cells treated with GNP
and GNP-HDM2 (described earlier in the Materials and Methods;
the Supplemental Materials and Methods). For analyzing p53-depen-
dent transactivation, real-time PCR for p53 targets such as Bax,
PUMA, Bcl2, and p21 was performed using the method detailed in
the Supplemental Materials and Methods. The primer sequence and
antibody details are provided in the Supplemental Materials and
Methods text, respectively (Table S10).362 Molecular Therapy: Nucleic Acids Vol. 9 December 2017Functional Effect of GNP-HDM2 Treatment on RB Cell Viability
and Cell Proliferation
The functional effect of GNP-HDM2 treatment on Y79 cell line was
studied by cell-cycle analysis and an apoptosis assay. Brieﬂy, Y79 cells
were seeded at a density of 1  106 per well in a 6-well plate. The
cultured cells were allowed to grow overnight and treated with
50 mM concentration of GNP-HDM2 and GNP (control) for 24 hr.
For the cell-cycle analysis, cells were harvested post-treatment and
washed in cold 1 PBS. After washing, cells were ﬁxed in 1 mL cold
70% (v/v) ethanol for 30 min on ice. The ﬁxed cells were washed twice
in ice-cold 1 PBS. Subsequently, cells were incubated with Telford’s
reagent and incubated for 3 hr at 37C and analyzed in a FACSCalibur
FlowCytometer. For the apoptosis assay, the cells post-treatment were
washed with cold 1 PBS. The cells were diluted in 1 annexin buffer
to achieve a density of 1  106 cells/mL. 5 mL of Alexa Fluor 488 an-
nexin V in 100 mL of cell suspension was incubated for 15 min. Subse-
quently, 1 mL of PI (propidium iodide) was added, and samples were
incubated for 5 min. After incubation, the cell suspension was mixed
with 300 mL 1 annexin-binding buffer and was kept on ice. This was
followed by analysis of the stained cells using ﬂow cytometry,
involving the measurement of ﬂuorescence emission at 530 and
617 nm using a 488-nm excitation laser, with 10,000 events recorded
for each sample. All experiments were performed in triplicate.
Microarray Investigation of Molecular Signaling during GNP-
HDM2 and GNP Treatment
Global gene expression analysiswas undertaken to investigate the regu-
lation of exponentially growing Y79 cells, which were treated with
50 mMofGNP-HDM2 orGNP for 24 hr and used formicroarray anal-
ysis. Brieﬂy, the treated Y79 cells were processed for RNA isolation
(RNeasy Mini Kit, QIAGEN, USA), followed by cDNA conversion,
using a recommended protocol from Affymetrix (https://www.
thermoﬁsher.com/us/en/home/life-science/microarray-analysis.html).
Genechip PrimeView Human Arrays were used for hybridization
(Affymetrix, Santa Clara, CA, USA), and scanning and feature extrac-
tionwas also doneusingGCOS software. Themicroarraydata are avail-
able in GEO (GEO: GSE92987). CEL ﬁles were analyzed utilizing the
R/Bioconductorpackage, oneChannelGUI.Affymetrixwhole-genome
expression raw data were RMA16 and were normalization and prepro-
cessed using GeneSpring GX (v.12.5) software (Agilent Technologies,
Santa Clara, CA, USA). Differentially expressed probe tests (Genes)
upon treatment in comparison to untreated cells were identiﬁed by
considering statistically signiﬁcantly enriched transcripts (p% 0.05).
The functional classiﬁcation of differentially expressed genes including
the GO enrichment analysis and KEGG pathway was performed using
the Database for Annotation, Visualization, and Integrated Discovery
(DAVID) tool. The cellular localization of the differential gene expres-
sion was carried out by analyzing the list in the Human protein refer-
ence database (http://www.hprd.org/). The gene identiﬁers and corre-
sponding expression and signiﬁcance values were uploaded into
ingenuity pathway analysis (IPA) software for the upstream regulator
analysis.AFisher’s exact test p value and activation score (z)were calcu-
lated to assess the signiﬁcance of enrichment of the gene expression
data for the genes downstream of an upstream regulator.
www.moleculartherapy.orgIn Silico MicroRNA Analysis
The gene-miRNA interactions for the differentially expressed genes
were obtained from the validated target module of miRwalk (v.2.0)
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/genepub.html).
Brieﬂy, the list of gene identiﬁers that were upregulated or downregu-
lated genes post-GNP-HDM2 were individually uploaded into the
validated gene-miRNA interaction information retrieval system
of miRwalk (v.2.0) (http://zmf.umm.uni-heidelberg.de/apps/zmf/
mirwalk2/genepub.html). The list of miRNAs obtained was ﬁltered
to include those which target at least 50 genes and ranked based on
the number of genes they affect. This approach was utilized for
both the upregulated and downregulated transcript lists.
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